For decades, aspirin has served as the quiet guardian of implanted heart valves — familiar, inexpensive, and largely unquestioned. A landmark Norwegian trial now challenges that assumption, finding that anticoagulant drugs not only prevent dangerous clot formation on artificial valves far more effectively, but do so with a safety profile that defies long-held clinical intuition. As heart valve procedures extend to younger patients who will live with these devices for decades, the question of how best to protect them has never carried greater consequence.
TAVI patients benefit from anticoagulants over aspirin, ACASA trial shows
Life-threatening bleeding occurred only in the aspirin group
Mark
So the trial compared anticoagulants directly to aspirin in TAVI patients. What made this comparison necessary?
Mimi
Until now, there wasn't a clear head-to-head study in patients who didn't already need anticoagulation for another reason. Guidelines were vague—use one or the other, but the evidence was thin.
Luke
Right, and that's important. The previous trials mixed anticoagulants with antiplatelet drugs, so you couldn't isolate which one was doing the work. This is the first clean comparison.
Mark
And the result was that anticoagulants cut clot formation by 45 percent. That's substantial.
Mimi
It is. And the clots they're measuring—hypo-attenuated leaflet thickening—aren't causing symptoms yet. But they're linked to valve failure down the road and to stroke and death.
Luke
Though I'd note: the link between subclinical thrombosis and those outcomes is established, but this trial didn't measure strokes or deaths as primary endpoints. It measured imaging findings.
Mark
Fair point. So what about the bleeding risk? That's usually the trade-off with anticoagulants.
Mimi
That's where it gets interesting. The anticoagulant group actually had fewer serious bleeding events. Life-threatening bleeding only happened in the aspirin group.
Luke
Ten deaths in the aspirin arm versus two in the anticoagulant arm. That's a real difference, but it's a small absolute number. The trial had 360 patients total, so we're talking about low event rates overall.
Mark
Still, if anticoagulants reduce clots AND don't increase bleeding, why wouldn't you use them?
Mimi
That's the question now. The findings could reshape guidelines, especially as TAVI is being offered to younger patients who'll have their valves for decades.
Luke
The caveat is that this was done in Norway across three hospitals in a specific age group—65 to 80. Generalizability to other populations or settings isn't guaranteed yet.
Il Polso
- Clots forming silently on implanted heart valves — a condition called leaflet thrombosis — have been quietly undermining valve durability and raising stroke risk in patients who feel no symptoms at all.
- The ACASA-TAVI trial exposed a 45% gap in clot formation between anticoagulant and aspirin groups, a difference stark enough to challenge the standard of care used in clinics worldwide.
- Counterintuitively, the drugs long feared for bleeding risk proved safer — life-threatening or fatal bleeding occurred exclusively in the aspirin group, forcing a reckoning with assumptions baked into clinical practice.
- With TAVI now offered to younger patients whose valves must last decades, the stakes of getting post-surgical drug therapy right have escalated dramatically.
- Cardiology's major guideline bodies now face pressure to absorb these findings and rewrite the playbook for post-TAVI care across millions of future patients.
For decades, aspirin has served as the quiet guardian of implanted heart valves — familiar, inexpensive, and largely unquestioned. A landmark Norwegian trial now challenges that assumption, finding that anticoagulant drugs not only prevent dangerous clot formation on artificial valves far more effectively, but do so with a safety profile that defies long-held clinical intuition. As heart valve procedures extend to younger patients who will live with these devices for decades, the question of how best to protect them has never carried greater consequence.
A clinical trial presented at the European Society of Cardiology Congress has challenged one of cardiology's quieter assumptions: that aspirin is the appropriate default therapy after transcatheter aortic valve implantation, or TAVI — a minimally invasive procedure in which a replacement valve is guided through an artery and seated inside the failing native valve without open surgery.
The ACASA-TAVI trial enrolled 360 patients aged 65 to 80 across three Norwegian hospitals, dividing them between a year of anticoagulant therapy and the current standard of aspirin or clopidogrel. At twelve months, imaging told a decisive story: only 17.2 percent of anticoagulant patients showed leaflet thrombosis — clot accumulation on the valve's moving parts — compared to 32.6 percent in the aspirin group. Even when subclinical and symptom-free, such thrombosis has been linked to premature valve failure, stroke, and death.
The safety findings proved equally disruptive. Clinicians have historically viewed anticoagulants as the riskier option, but the trial found serious bleeding, stroke, or death occurred in 7.5 percent of the anticoagulant group versus 10.6 percent on aspirin. More strikingly, every life-threatening or fatal bleeding event occurred in the aspirin arm — ten deaths compared to two.
Principal investigator Dr. Øyvind Lie of Oslo University Hospital noted that no head-to-head comparison had previously been conducted in patients without an independent reason for anticoagulation, leaving guidelines without clear direction. His team's results, he suggested, may now provide that direction — particularly as TAVI expands to younger patients for whom long-term valve durability is not an abstraction but a lived necessity. Whether major cardiology organizations will update their recommendations in response remains the trial's most consequential open question.
A major clinical trial has upended conventional thinking about how to protect artificial heart valves after they are implanted. Researchers found that anticoagulant drugs—the kind typically reserved for patients with atrial fibrillation or clotting disorders—work substantially better than aspirin at preventing dangerous clot formation on the new valves, and they do so without increasing the risk of serious bleeding.
The finding comes from the ACASA-TAVI trial, presented this week at the European Society of Cardiology Congress and published simultaneously in JAMA. The study tracked 360 patients between ages 65 and 80 who had undergone transcatheter aortic valve implantation, a minimally invasive procedure in which a replacement valve is threaded through an artery and positioned inside the diseased aortic valve without open surgery. Half the patients received an anticoagulant—apixaban, edoxaban, or rivaroxaban—for a year. The other half received aspirin or clopidogrel, the current standard of care.
At the 12-month mark, imaging revealed a stark difference. Among patients taking anticoagulants, only 17.2 percent showed signs of leaflet thrombosis, a subtle but potentially dangerous accumulation of clots on the valve leaflets. In the aspirin group, that figure reached 32.6 percent—a 45 percent reduction in favor of anticoagulation. The finding matters because subclinical thrombosis, even when it causes no immediate symptoms, has been linked to premature valve dysfunction, stroke, and death.
Dr. Øyvind Lie, the trial's principal investigator from Oslo University Hospital Rikshospitalet in Norway, explained the gap that prompted the research. "Thrombus formation on the leaflets of implanted bioprosthetic valves is a potentially preventable cause of early valve dysfunction," he said. Current guidelines offer little clarity: they recommend either an antiplatelet agent like aspirin or an anticoagulant, but only if a patient has an independent medical reason for anticoagulation. No head-to-head comparison had been done in patients without such a reason—until now.
The safety data proved equally important. Clinicians have long worried that anticoagulants carry a higher bleeding risk than aspirin. The trial found the opposite. The anticoagulant group experienced a 7.5 percent rate of major bleeding, stroke, or death, compared to 10.6 percent in the aspirin group. More tellingly, life-threatening or fatal bleeding occurred only in the aspirin group—ten deaths versus two in the anticoagulant arm. "Clinicians may perceive the bleeding risk of anticoagulants to be higher than that of antiplatelet agents," Lie noted, "but we found in this study that life-threatening and lethal bleeding occurred only in patients in the ASA group."
The timing of this finding carries particular weight. TAVI has grown exponentially since the first successful procedure two decades ago, and the procedure is now being offered to younger patients with longer life expectancies. For these patients, the durability of the bioprosthetic valve becomes critical. A valve that develops thrombosis early may fail sooner, requiring repeat intervention. If anticoagulation can substantially reduce that risk without added danger, it could reshape how millions of patients are treated after the procedure.
Lie cautioned that the trial was conducted across three hospitals in Norway and involved a specific age group, but he suggested the results may establish a new standard. "We were able to show substantial reductions in signs of subclinical leaflet thrombosis with NOAC monotherapy, without compromising safety," he said. "Results from the ACASA-TAVI trial may establish a new antithrombotic treatment paradigm after TAVI and could be used to inform future guidelines." The next step will be whether major cardiology organizations adopt these findings and update their recommendations for post-TAVI care.
Citazioni salienti
Thrombus formation on the leaflets of implanted bioprosthetic valves is a potentially preventable cause of early valve dysfunction and has been linked to increased risk of stroke and death.— Dr. Øyvind Lie, principal investigator, Oslo University Hospital Rikshospitalet
Results from the ACASA-TAVI trial may establish a new antithrombotic treatment paradigm after TAVI and could be used to inform future guidelines.— Dr. Øyvind Lie
Vuoi la storia completa?
Leggi l'originale su Medical Xpress ↗
Health & Medicine